Speaker illustration

Doctor Vidya Perera

Bristol Myers Squibb, Princeton (United States of America)

First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-986177/JNJ-70033093, a direct, reversible, small molecule Factor XIa inhibitor in healthy volunteers

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Anticoagulants

Session: Antithrombotic Therapy Update

Thumbnail

Single-dose pharmacokinetics of BMS-986177/JNJ-70033093 in participants with mild or moderate hepatic impairment compared to healthy participants

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Anticoagulants

Session: Pharmacology and Pharmacotherapy ePosters

Thumbnail

This platform is supported by

logo Novo Nordisk